Navigation Links
Leading AIDS Groups Turn Up The Heat on '08 Presidential Candidates
Date:11/28/2007

chmarks and accountability mechanisms is a

key plank in the AIDSVote.org platform. The U.S. requires nations

applying for billions of dollars in federal funding under the

President's Emergency Plan for AIDS Relief (PEPFAR) to develop such

plans -- but the U.S. has yet to develop its own national strategy to

combat the domestic HIV/AIDS crisis.

AIDSVote.org is a nonpartisan voter and candidate education campaign endorsed by dozens of leading AIDS organizations including the Campaign to End AIDS, AIDS Action Council, the National Association of People with AIDS, the Global AIDS Alliance, and HealthGAP.

While not endorsing candidates for public office, AIDSVote.org is dedicated to ensuring that presidential candidates know about the best possible strategies to make progress against HIV/AIDS in the U.S. and abroad. The website includes domestic and global AIDS platforms, which detail how the next president of the U.S. can end AIDS in places as remote as South Africa and as close as South Carolina.

"We not only hope to better inform voters about how important HIV/AIDS policy issues and the need for a national AIDS strategy are in the election but also hope to better inform the candidates themselves," said Rebecca Haag, AIDS Action Council executive director.

"AIDSVote.org wants to make sure that whoever moves into 1600 Pennsylvania Avenue in January 2009 will make ending the AIDS epidemic a top priority," said David Ernesto Munar, vice president at the AIDS Foundation of Chicago. "It's a matter of life and death."

The answers to the candidate questionnaire and GMHC's candidate report are only the first installments that will be available on AIDSVote.org, which will track the presidential candidates' positions on HIV/AIDS up until the November 2008 election.


'/>"/>
SOURCE Gay Men's Health Crisis
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
3. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
4. Influenza is Leading Cause of Vaccine-Preventable Deaths for Kids; Despite CDC Recommendations, Moms Still Dont Vaccinate
5. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
6. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
7. Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection
8. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
9. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
10. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 2Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 3Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 4Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 5Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 6Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 7Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 8Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 2Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 3Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 4Efficacy and Safety Profile of Basilea's Alitretinoin for Severe,Refractory Chronic Hand Eczema Confirmed by Data Shown at European,Dermatology Congress 5